OnabotulinumtoxinA for Hemicrania Continua: open label experience in 9 patients

Table 2 Headache scores pre- and post- treatment with OnabotulinumtoxinA

ID	Average headache days/month			Average moderate -severe days/month*			Average daily headache hours			Average daily VRS			Change in headache load (%)	Subjective estimate of response	Estimated duration of response (weeks)
ID	Pre	Post	Change %	Pre	Post	Change %	Pre	Post	Change %	Pre	Post	Change %	Change in headache load (%)	Subjective estimate of response	Estimated duration of response (weeks)
1	30	0	100	20	0	100	24	0	100	5	0	100	100	>90%	16
2	30	0	100	15	0	100	24	0	100	5	0	100	100	>90%	20
3	30	30	0	30	19	37	24	24	0	8	6	25	20	30-50%	5
4	30	30	0	30	30	0	24	24	0	7	6	14	0	0	0
5	30	3	90	30	3	90	24	6	75	7	10	0	98	80-90%	12
6	30	30	0	30	23	23	15	16	0	7	6	14	0	15-25%	4
7	30	22	27	21	13	27	24	7	71	7	4	43	55	40%	6
8	30	2	93	30	0	100	24	8	67	9	2	78	99	80-90%	6
9	30	0	100	30	0	100	24	0	100	8	0	100	100	>90%	9
Mean	30	13	57	25	10	64	23	9	57	7	4	51	62		8
Median (Range)	30 (30)	3 (0–30)	90 (0–100)	30 (15–30)	3 (0–30)	80 (0–100)	24 (15–24)	7 (0–24)	71 (0–100)	7 (5-9)	4 (0–10)	43 (0–100)	98 (0–100)		6 (0–20)

*Response defined as 50% or more improvement in average moderate-severe headache days/month; VRS, Verbal Rating Scale; Pre, Pre-treatment; Post, Post-final treatment.

ISSN: 1129-2377